• Profile
Close

Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa The SHARPS randomized clinical trial

JAMA Nov 17, 2021

Bechara FG, Podda M, Prens EP, et al. - Researchers aimed at determining the efficacy and safety of adalimumab in conjunction with wide-excision surgery followed by secondary intention healing in adult patients with moderate to severe hidradenitis suppurativa (HS).

  • The Safety and Efficacy of Adalimumab for Hidradenitis Suppurativa Peri-Surgically (SHARPS) trial is a randomized clinical trial involving 206 patients.

  • HS clinical response was achieved across all body regions in significantly more patients receiving adalimumab vs placebo at week 12 along with significantly more improvements in quality of life.

  • Patients with HS can be effectively managed using adalimumab, with no need to interrupt treatment prior to surgery.

  • Considering these findings, medical treatment decisions can be made for cases with HS who are candidates for surgery.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay